Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients

Table 1 Differentially expressed proteins identified by 2-DE

Spot no.	Protein	Gene name	Function	Accession	Theoretical M_r/pI^a	Score^b	No. of pep.^c	Expression level (AIH/Control) ^d	iTRAQ validation (116/114)^e
1	serum amyloid A2	SAA2	acute phase reactant	gi6755394	13613.5/6.41	122	2	↑6.56 ± 0.2	N/A^f
2	serum amyloid A1	SAA1	acute phase reactant	gi404753	13691.5/6.5	45	2	↑14.72 ± 2.1	N/A
3	alpha-fetoprotein	AFP	estrogens, fatty acids and metals binding	gi191765	47194.9/5.47	172	7	↑3.00 ± 0.9	N/A
4	complement C3	C3	activation immune	gi126518317	187904/6.31	44	3	↑2.41 ± 0.06	2.19
5	glutathione peroxidase	GPX4	oxidative damage protecting calcium ion binding	gi2673845	22290.59/6.74	54	3	↑4.16 ± 0.18	N/A
6	fumarylacetoacetase	FAH	enzyme regulator activity; protein binding	gi253320	46416/6.56	43	4	↑12.4 ± 0.78	N/A
7	alpha-2-macroglobulin	A2M	activation immune	gi110347469	167144/6.17	41	3	↑1.98 ± 0.23	1.61
8	interleukin 17 F	IL17F	actin/ vitamin D binding	gi22003916	17008.8/9.05	40	2	↓8.3 ± 1.11	N/A
9	vitaminD-binding protein precursor	GC	vitamin transporter activity	gi51172612	53565/5.39	56	3	↓2.08 ± 0.2	N/A

^aTheoretical molecular weight (kDa) and pI from the ExPASy database.
^bProbability-based Mascot scores.
^cNumber of unique peptides identified by MS/MS.
^dAverage expression level of altered proteins by 2-DE and MS from three independent analyses (mean ± SD) (↑,increased; ↓, decreased).
^eThe differential expression of proteins in serum from AIH patients and controls was validated by iTRAQ (average of the two experiments, control: 114; AIH: 116).
^fN/A, Not analyzed by iTRAQ.

ISSN: 1479-5876